Skip to main content
Log in

Infection

Prostate biopsy—infection and prior fluoroquinolone exposure

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Prostate cancer screening has led to an increase in transrectal-ultrasonography (TRUS)-guided prostate biopsies. However, clinicians are becoming increasingly concerned that fluoroquinolone-resistant organisms are the cause of infectious complications in patients who have undergone this procedure. Two separate studies have shown that patients treated with fluoroquinolone prior to transrectal biopsy are at an increased risk of infectious complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hodge, K. K., McNeal, J. E. & Stamey, T. A. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J. Urol. 142, 66–70 (1989).

    Article  CAS  PubMed  Google Scholar 

  2. Naughton, C. K., Miller, D. C., Mager, D. E., Ornstein, D. K. & Catalona, W. J. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J. Urol. 164, 388–392 (2000).

    Article  CAS  PubMed  Google Scholar 

  3. Nam, R. K. et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J. Urol. 183, 963–968 (2010).

    Article  PubMed  Google Scholar 

  4. Liss, M. A. et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J. Urol. 185, 1283–1288 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Wolf, J. S., Jr et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J. Urol. 179, 1379–1390 (2008).

    Article  PubMed  Google Scholar 

  6. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61–71 (2011).

    Article  PubMed  Google Scholar 

  7. Mosharafa, A. A., Torky, M. H., El Said, W. M. & Meshref, A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 78, 511–514 (2011).

    Article  PubMed  Google Scholar 

  8. Akduman, B. et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 78, 250–255 (2011).

    Article  PubMed  Google Scholar 

  9. Horcajada, J. P. et al. High prevalence of extended-spectrum beta-lactamase-producing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol. Urology 74, 1195–1199 (2009).

    Article  PubMed  Google Scholar 

  10. Batura, D., Rao, G. G. & Nielsen, P. B. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJUI 106, 1017–1020 (2010).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I would like to thank Dr Ralph V. Clayman for his critical review of this manuscript.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liss, M. Prostate biopsy—infection and prior fluoroquinolone exposure. Nat Rev Urol 8, 592–594 (2011). https://doi.org/10.1038/nrurol.2011.153

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2011.153

  • Springer Nature Limited

Navigation